CERO (CERo Therapeutics Holdings) יחס שווי שוק לשווי בספרים

CERo Therapeutics maintains its financial health through previously raised capital, as operational cash flow has not yet commenced. The market's revaluation coefficient of balance sheet capital confirms the current trend, where the -0.01 mark characterizes this parameter. The company's stability depends on grants and the outcomes of immunotherapy clinical trials. High pricing power is driven by unique T-cell technologies for combating oncology.

For a defensive portfolio, fundamental screening begins with an analysis of asset value. This multiple compares the market value of CERo Therapeutics (CERO) to its book value, determining the degree of the company's overvaluation. For biopharmaceuticals, where success depends on scientific breakthroughs rather than economic cycles, this metric reflects market expectations for R&D. Analyzing changes in the price-to-book multiple allows for the identification of equilibrium zones between capital and the value of innovation.